Management Team

Julie Cherrington, Ph.D.

President and CEO

Dr. Julie M. Cherrington, Ph.D. is a life science executive with extensive experience bringing drugs into the clinic and through to commercialization. She has been a key contributor to the successful development of multiple FDA approved products, including SUTENT™, Palladia™, Vistide™, Viread™, and Hepsera™.

Julie currently serves as President and CEO of Arch Oncology, an immuno-oncology company. Most recently, Julie served as President and CEO of Revitope, also an immune-oncology company and before that was President and CEO of Zenith Epigenetics, a bromodomain inhibitor company. From 2009 to 2014, Julie was President and CEO of Pathway Therapeutics, a clinical stage company advancing targeted kinase inhibitors. Prior to joining Pathway, she served as President and EVP of R&D of Phenomix Corporation. Prior to joining Phenomix in 2003, Julie was vice president of preclinical and clinical research at SUGEN, a Pharmacia/Pfizer company. Julie began her career at Gilead Sciences where she held a range of positions of increasing responsibility.

She has served on the Boards of Directors of Chemgenex, Progen and Xenome. She is currently a member of the Scientific Advisory Board of the Clearity Foundation and is an advisor in entrepreneurship initiatives at the California Life Sciences Institute (CLSI), UC San Francisco, and UC Davis.

Robert W. Karr, M.D.

Chief Scientific Officer

Dr. Karr is currently Arch Oncology’s Chief Scientific Officer, a position he has held since 2016. He joined the company in 2010, serving as its first Chief Executive Officer. Dr. Karr brings extensive experience in the pharmaceutical and biotechnology industries with expertise ranging the spectrum of drug development, from discovery research to clinical trial execution. Prior to Arch Oncology and its predecessor companies, Dr. Karr held senior management positions in Idera, Pfizer, and Warner-Lambert.

Dr. Karr completed his internship and residency in internal medicine at Washington University School of Medicine and served as faculty member at both the University of Iowa College of Medicine and Washington University School of Medicine. He received his B.S. from Southwestern University and his M.D. from the University of Texas Medical Branch.

Pamela T. Manning, Ph.D.

Vice President of Research

Dr. Manning has served as Vice President of Research since co-founding the company in 2006. She has over 20 years of experience in drug discovery within the pharmaceutical industry including positions at G.D. Searle, Pharmacia and Pfizer. Dr. Manning has considerable experience developing drug candidates from discovery through IND-enabling studies and early clinical development. Her broad expertise in pharmacology spans multiple therapeutic areas including neuroscience, cardiovascular, oncology, inflammation and pain. She is also internationally recognized in the field of nitric oxide research.

Dr. Manning received her Ph.D. in Pharmacology from the Ohio State University, completed postdoctoral studies in pharmacology at Washington University School of Medicine and holds an M.S. and B.S. from Wright State University.

William A. Frazier, Ph.D.

Scientific Co-Founder and Advisor

Dr. Frazier is a professor of Biochemistry, Molecular Biophysics, and Cell Biology at Washington University School of Medicine. He discovered that CD47 is a receptor for thrombospondin-1. Having contributed to over 140 publications, Dr. Frazier has been a leader in the field of CD47-mediated signaling pathways for many years. He co-founded the company in 2006 based on research from his laboratory and that of his collaborators at the National Institutes of Health.

Dr. Frazier holds a B.A. from Johns Hopkins University and a Ph.D. from Washington University in St. Louis.